AstraZeneca shares fall 7% after cancer drug Gefitinib plea shot down
- Telangana bill passage shows country can take difficult decisions: Prime Minister
- Top General speaks on 2012 troop movement: "Def Secy summoned me late night, said highest seat of power was worried, troops must go back quickly"
- âTroop movement shouldâve been avoided if they knew (V K Singhâs) court dateâ
- The 2012 troop movement investigations
- India slams Pakistan for allowing Masood Azhar to spew venom
Shares of AstraZeneca Pharma today tumbled over 7 per cent, after the Intellectual Property Appellate Board (IPAB) turned down the drug firm's plea for a patent on the lung cancer drug Gefitinib.
Following the move, shares of the company opened weak and as the trade progressed it tanked 7.38 per cent to Rs 1,449.50 on the BSE.
At NSE, the scrip slipped 7.65 per cent to Rs 1,444.05.
Reacting on the development, the company said it is disappointed and is evaluating its options.
"We are disappointed by the Intellectual Property Appellate Board's decision.
We are confident in the validity of the claims in this patent application and are now evaluating our next steps," AstraZeneca said in a statement.
IPAB on November 26 upheld its earlier decision to refuse AstraZeneca a patent claim in 2007, citing lack of invention.
Decline in the stock was in contrast with a robust stock market where the benchmark index Sensex was trading at 19,093.42, up 251.34 points.
- What should common man expect when PM’s killers are freed: Rahul on Jayalalithaa’s decision
- Anna Hazare says, I support Mamata Banerjee for her ideas
- The regressive state | The Indian Express
- Top General speaks: Def Secy summoned me late night, said highest seat of power was worried, troops must go back quickly